Literature DB >> 26781614

ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.

Kana Sakamoto1,2, Hideki Nakasone2, Yuki Togashi1,3, Seiji Sakata1, Naoko Tsuyama3, Satoko Baba1, Akito Dobashi1, Reimi Asaka1,3, Chien-Chen Tsai4, Shih-Sung Chuang5,6,7, Koji Izutsu8, Yoshinobu Kanda2, Kengo Takeuchi9,10.   

Abstract

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+LBCL) is a rare, aggressive B-cell lymphoma with ALK fusion genes. Histopathologically, the ALK immunohistochemical staining pattern is suggestive of the fusion partner of ALK. Here, we examined an ALK+LBCL case showing a unique diffuse cytoplasmic ALK staining pattern and identified EML4-ALK, which has not previously been reported in ALK+LBCL. Furthermore, to clarify whether the prognosis differs depending on the staining pattern, we reviewed 112 previously reported cases, and analyzed immunohistochemical markers and clinical data stratified by the staining pattern. We found that ALK staining can be classified into a granular cytoplasmic staining (GCS) or a non-GCS patterns. Sixty-four adult cases for which both the ALK staining pattern and survival time were reported were further analyzed for survival trends. The non-GCS pattern was significantly associated with inferior overall survival (P = 0.031). This difference remained significant after adjusting for age and clinical stage (hazard ratio 5.08, 95 % CI 1.88-13.7, P = 0.0013). Given that the ALK immunohistochemical staining pattern is associated with the ALK fusion partner, the present results suggest that the prognosis for ALK+LBCL differs depending on the ALK fusion partner.

Entities:  

Keywords:  Anaplastic lymphoma kinase; Anaplastic lymphoma kinase-positive large B-cell lymphoma; EML4-ALK; Fusion partner; Immunohistochemistry

Mesh:

Substances:

Year:  2016        PMID: 26781614     DOI: 10.1007/s12185-016-1934-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  45 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas.

Authors:  Clare Bedwell; David Rowe; Deborah Moulton; Gail Jones; Nick Bown; Chris M Bacon
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

3.  Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.

Authors:  Maxi Wass; Timo Behlendorf; Bärbel Schädlich; Anja Mottok; Andreas Rosenwald; Hans-Joachim Schmoll; Karin Jordan
Journal:  Eur J Haematol       Date:  2014-01-10       Impact factor: 2.997

4.  Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma.

Authors:  Seung Eun Lee; So Young Kang; Kengo Takeuchi; Young Hyeh Ko
Journal:  Hematol Oncol       Date:  2014-01-27       Impact factor: 5.271

Review 5.  ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.

Authors:  Zbigniew Rudzki; Małgorzata Rucińska; Wojciech Jurczak; Aleksander B Skotnicki; Magdalena Maramorosz-Kurianowicz; Andrzej Mruk; Krystyna Piróg; Graźyna Utych; Piotr Bodzioch; Maria Srebro-Stariczyk; Iwona Włodarska; Jerzy Stachura
Journal:  Pol J Pathol       Date:  2005       Impact factor: 1.072

6.  Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.

Authors:  R Suzuki; Y Kagami; K Takeuchi; M Kami; M Okamoto; R Ichinohasama; N Mori; M Kojima; T Yoshino; H Yamabe; M Shiota; S Mori; M Ogura; N Hamajima; M Seto; T Suchi; Y Morishima; S Nakamura
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

7.  STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target.

Authors:  Emanuele S G d'Amore; Carlo Visco; Andrea Menin; Barbara Famengo; Paolo Bonvini; Elena Lazzari
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

8.  Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.

Authors:  Camille Laurent; Catherine Do; Randy D Gascoyne; Laurence Lamant; Loïc Ysebaert; Guy Laurent; Georges Delsol; Pierre Brousset
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

9.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity.

Authors:  Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2009-03-13

10.  KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.

Authors:  Yuki Togashi; Manabu Soda; Seiji Sakata; Emiko Sugawara; Satoko Hatano; Reimi Asaka; Takashi Nakajima; Hiroyuki Mano; Kengo Takeuchi
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

View more
  6 in total

Review 1.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

2.  Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases.

Authors:  Brendan C Dickson; David Swanson; George S Charames; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

Review 3.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

4.  Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.

Authors:  Jo-Anne van der Krogt; Marlies Vanden Bempt; Julio Finalet Ferreiro; Nicole Mentens; Kris Jacobs; Ursula Pluys; Kathleen Doms; Ellen Geerdens; Anne Uyttebroeck; Pascal Pierre; Lucienne Michaux; Timothy Devos; Peter Vandenberghe; Thomas Tousseyn; Jan Cools; Iwona Wlodarska
Journal:  Haematologica       Date:  2017-06-28       Impact factor: 9.941

Review 5.  Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Authors:  Geeta Geeta Sharma; Ines Mota; Luca Mologni; Enrico Patrucco; Carlo Gambacorti-Passerini; Roberto Chiarle
Journal:  Cancers (Basel)       Date:  2018-02-28       Impact factor: 6.639

6.  Pre-configuring chromatin architecture with histone modifications guides hematopoietic stem cell formation in mouse embryos.

Authors:  Chen C Li; Guangyu Zhang; Junjie Du; Di Liu; Zongcheng Li; Yanli Ni; Jie Zhou; Yunqiao Li; Siyuan Hou; Xiaona Zheng; Yu Lan; Bing Liu; Aibin He
Journal:  Nat Commun       Date:  2022-01-17       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.